Myriad Genetics (MYGN) Current Assets (2010 - 2026)

Myriad Genetics has disclosed Current Assets across 17 years of filings, most recently posting $312.8 million for Q1 2026.

• In Q1 2026, Current Assets rose 8.91% year-over-year to $312.8 million; the TTM figure through Mar 2026 stood at $312.8 million (up 8.91% YoY), while the FY2025 annual figure was $332.6 million, up 11.61% from the prior year.
• Current Assets fell to $312.8 million in Q1 2026, from $332.6 million in the prior quarter.
• Over the last five years, Current Assets for MYGN reached as high as $427.4 million in Q1 2022 and fell as low as $261.6 million in Q1 2023.
• The 5-year median for Current Assets is $294.3 million (2023), against an average of $311.2 million.
• The widest YoY moves for Current Assets: up 29.83% in 2022, down 43.36% in 2022.
• A 5-year view of Current Assets shows it stood at $274.6 million in 2022, then grew by 14.2% to $313.6 million in 2023, then decreased by 4.97% to $298.0 million in 2024, then rose by 11.61% to $332.6 million in 2025, then dropped by 5.95% to $312.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $312.8 million, $332.6 million, and $344.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.